Shots:
- The UK’s MHRA has approved Xoanacyl (ferric citrate complex) for the treatment of concomitant elevated serum phosphorus & iron deficiency in CKD adults via International Recognition Procedure (Route B), following EC’s approval in Jun 2025
- In Dec 2022, Averoa obtained an exclusive license from Akebia Therapeutics to develop & commercialize Xoanacyl in the EEA, Switzerland, the UK, Turkey, Israel, & select Eastern EU countries
- Xoanacyl (PO) provides ferric iron supplementation while reducing phosphorus absorption, thereby simplifying treatment regimens & improving patient outcomes
Ref: Averoa | Image: Averoa | Press Release
Related News:- Averoa Receives the EC’s Approval for Xoanacyl to Treat Chronic Kidney Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
